Roche open to big acquisitions 'if it makes scientific and financial sense', CEO tells NZZ am Sonntag

Earlier this year it was reported that U.S. biotech company Roivant Sciences was in talks to sell to Roche an experimental drug to treat inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, in a deal that could be valued at more than $7 billion.

Both companies declined to comment on the matter at the time.

Schinecker declined to comment to the newspaper on the size of any potential deals by Roche. The company is due to hold an investor day on Monday where it will outline its strategy and give updates on its product pipeline.

"With every possible acquisition, we ask ourselves whether the potential expenditure can be earned back," he said.

"We still have the strategic flexibility for acquisitions," he added, when asked if Roche had enough funding to support a buying spree after buying the shares back from Novartis.